Ganesh S. Mhaske, Sanket R. Thorat, Varun S. Pawar, Ravindra S. Pawar, S. R. Jambhulkar, Omkar A. Ghumre
{"title":"Computational Molecular Docking and In-Silico, ADMET Prediction Studies of\nQuinoline Derivatives as EPHB4 Inhibitor","authors":"Ganesh S. Mhaske, Sanket R. Thorat, Varun S. Pawar, Ravindra S. Pawar, S. R. Jambhulkar, Omkar A. Ghumre","doi":"10.2174/012210299x265033240116113623","DOIUrl":null,"url":null,"abstract":"\n\nThe creation and development of novel chemical entities is made possible by numerous computer-aided drug design techniques. The ability to\nvisualize the ligand-target interaction and forecast the important holding pocket locations and affinities of ligands to their intended macromolecules\nis made possible by pharmacophore-based drug design and understanding in-silico methodologies.\n\n\n\nThe aim of the current investigation was to find novel 2-chloroquinoline-3-carboxamide derivatives that target the Ephrin B4 (EPHB4) receptor to\ntreat cancer.\n\n\n\nChem Axon Marvin Sketch 5.11.5 was used to create derivatives of 2-chloroquinoline-3-carboxamide. The physicochemical characteristics of\ncompounds as well as their toxicity were predicted using SwissADME& the admet SAR online software’s. Molecular docking technology was\nused to examine the ligand-receptor interactions of 2-chloroquinoline-3-carboxamide derivatives with the target receptor (PDB- 6FNM) using a\nvariety of software’s, including Autodock1.1.2,Procheck, ProtParam tool, Biovia Discovery Studio Visualizer v20.1.0.19295, MGL Tools 1.5.6,\nPyMOL, and were all included.\n\n\n\nAll developed compounds were determined to be orally bioavailable, less toxic, and have acceptable pharmacokinetic properties according to in\nsilico studies. In comparison to the traditional medication Erdafitnib, all new compounds displayed higher docking scores.\n\n\n\nThe increase in binding energy and the number of H-bonds created by novel derivatives with interactions at distances below 3.40A provide a\nhelpful starting point for formulating and synthesizing compounds that are most suitable for additional research. The application of the 2-\nchloroquinoline-3-carboxamide moiety as a potential new cancer treatment candidate is supported by its pharmacokinetics &toxicological profile,\nwhich may aid medicinal chemists in conducting more in-depth in vitro, in vivo chemical and pharmacological studies.\n","PeriodicalId":505533,"journal":{"name":"Current Indian Science","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Indian Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/012210299x265033240116113623","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The creation and development of novel chemical entities is made possible by numerous computer-aided drug design techniques. The ability to
visualize the ligand-target interaction and forecast the important holding pocket locations and affinities of ligands to their intended macromolecules
is made possible by pharmacophore-based drug design and understanding in-silico methodologies.
The aim of the current investigation was to find novel 2-chloroquinoline-3-carboxamide derivatives that target the Ephrin B4 (EPHB4) receptor to
treat cancer.
Chem Axon Marvin Sketch 5.11.5 was used to create derivatives of 2-chloroquinoline-3-carboxamide. The physicochemical characteristics of
compounds as well as their toxicity were predicted using SwissADME& the admet SAR online software’s. Molecular docking technology was
used to examine the ligand-receptor interactions of 2-chloroquinoline-3-carboxamide derivatives with the target receptor (PDB- 6FNM) using a
variety of software’s, including Autodock1.1.2,Procheck, ProtParam tool, Biovia Discovery Studio Visualizer v20.1.0.19295, MGL Tools 1.5.6,
PyMOL, and were all included.
All developed compounds were determined to be orally bioavailable, less toxic, and have acceptable pharmacokinetic properties according to in
silico studies. In comparison to the traditional medication Erdafitnib, all new compounds displayed higher docking scores.
The increase in binding energy and the number of H-bonds created by novel derivatives with interactions at distances below 3.40A provide a
helpful starting point for formulating and synthesizing compounds that are most suitable for additional research. The application of the 2-
chloroquinoline-3-carboxamide moiety as a potential new cancer treatment candidate is supported by its pharmacokinetics &toxicological profile,
which may aid medicinal chemists in conducting more in-depth in vitro, in vivo chemical and pharmacological studies.